Business
SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
SALT LAKE CITY, May 10, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health
About this update from Sera Prognostics, Inc.
[{"type":"text","content":"SALT LAKE CITY, May 10, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter ended March 31, 2022.\n\n \n \n \n \n \n \n\n \nRecent Highlights:\nSimplified and streamlined the PreTRM® test ordering process, resulting in increased numbers of orders and ordering physicians. These positive trends appear to be continuing into the current quarter.Added accomplished business and health services leader, Dr. Jane F. Barlow, to our Board, bringing deep expertise in bringing novel products and services to the market, through operations, and strategy development and board experiences in pioneering a variety of novel health services to support Sera's quest to improve pregnancy outcomes for mothers and babies.Engaged in active dialogue with government officials and organizations to reduce healthcare disparities among underserved communities by utilizing our PreTRM® Test to identify mothers and babies at risk for spontaneous preterm birth so that proactive care and intervention can be leveraged for a better healthcare outcome.Continued pipeline progress including final validation of the first mid-pregnancy proteomic prognostic biomarker for preeclampsia by mid-year 2022, as a complement to Sera's PreTRM® test. Preeclampsia affects approximately 5-8% of pregnancies; preterm birth affects approximately 10% of all pregnancies.\"As we build awareness, we are seeing increases in orders and improvement in other key commercial metrics. This reflects the growing recognition of the benefit of our PreTRM® Test, which fosters increased adoption with payors, care providers and patients,\" stated Gregory C. Critchfield, MD, MS, Chairman and CEO of Sera Prognostics. \"At the same time, we are also encouraged by additional strong clinical utility and health economic data of Sera's PreTRM® test-and-treat strategy, that we expect to share later this month, and by the ramp up of enrollment in our PRIME study with Anthem and HealthCore. New sites have come online and the study is on track for the interim look readout to take place in 2023. The PRIME study is designed to further demonstrate the value of implementing the PreTRM® prevention strategy t...